A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients

Overview of attention for article published in World Journal of Urology, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 1 news outlet

twitter: 2 X users

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 33 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

FDA Approves Subcutaneous Depot Formulation of Leuprolide Mesylate for Prostate Cancer

OncLive, 27 May 2021

The regulatory decision is based on data from a phase 3 study that was conducted in a total of 137 patients with advanced…